The menopause is a normal life event for women and not an illness or medical condition. Despite this, menopause can predispose vulnerable women to distressing symptoms that impact adversely on their quality of life and to long term medical conditions such as osteoporosis, cardiovascular disease and dementia. Many healthcare professionals are uncertain about the management of the menopause, and this leads to many women not receiving treatment which is often beneficial to them. This article will cover the diagnosis of the menopause including premature ovarian insufficiency. Some of the health risks of the menopause will be discussed and treatment of the menopause, with a particular focus on hormone replacement therapy, will be covered in detail.
Get full access to this article
View all access options for this article.
References
1.
AchilliCPundirJRamanathanPet al.(2017) Efficacy and safety of transdermal testosterone in postmenopausal women with hypoactive sexual desire disorder: A systematic review and meta-analysis. Fertility and Sterility107(2): 475–482. DOI: 10.1016/j.fertnstert.2016.10.028.
2.
AndersonGLChlebowskiRTAragakiAKet al.(2012) Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: Extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol13(5): 476–486. DOI: 10.1016/S1470-2045(12)70075-X.
3.
Boardman HM, Hartley L, Eisinga A, et al. (2015) Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Systematic Review Issue 3: CD002229. DOI: 10.1002/14651858.CD002229.pub4.
4.
CagnacciACarboneMPalmaF (2016) Prevalence and association between objective signs and subjective symptoms of vaginal atrophy: The AGATA study. Menopause23(10): 1139–1145. DOI: 10.1097/GME.0000000000000675.
5.
CanonicoMPlu-BureauGLoweGDet al.(2008) Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: Systematic review and meta-analysis. British Medical Journal336: 1227–1231. DOI: 10.1136/bmj.39555.441944.BE.
6.
CartwrightBRobinsonJSeedPTet al.(2016) Hormone replacement therapy versus the combined oral contraceptive pill in premature ovarian failure: A randomized controlled trial of the effects on bone mineral density. Journal of Clinical Endocrinology and Metabolism101(9): 3497–3505. DOI: 10.1210/jc.2015-4063.
7.
EdwardsDPanayN (2016) Treating vulvovaginal atrophy/genitourinary syndrome of menopause: How important is vaginal lubricant and moisturizer composition?Climacteric19(2): 151–161. DOI: 10.3109/13697137.2015.1124259.
FournierABerrinoFRiboliEet al.(2005) Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. International Journal of Cancer114: 448–854. DOI: 10.1002/ijc.20710.
GlaserRYorkAEDimitrakakisC (2011) Beneficial effects of testosterone therapy in women measured by the validated Menopause Rating Scale (MRS). Maturitas68(4): 355–361. DOI: 10.1016/j.maturitas.2010.12.001.
12.
ImtiazBTuppurainenMRikkonenTet al.(2017) Postmenopausal hormone therapy and Alzheimer disease: A prospective cohort study. Neurology88: 1062–1068. DOI: 10.1212/WNL.0000000000003696.
13.
LealJGrayAMPrieto-AlhambraDet al.(2016) Impact of hip fracture on hospital care costs: A population-based study. Osteoporosis International27: 549–558. DOI: 10.1007/s00198-015-3277-9.
14.
LyytinenHPukkalaEYlikorkalaO (2009) Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obstetrics and Gynecology113: 65–73. DOI: 10.1097/AOG.0b013e31818e8cd6.
15.
MacBrideMRhodesDShusterL (2010) Vulvovaginal atrophy. Mayo Clinic Proceedings85(1): 87–94. DOI: 10.4065/mcp.2009.0413.
16.
Marjoribanks J, Farquhar C, Roberts H, et al. (2012) Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Systematic Review Issue 7: CD004143. DOI: 10.1002/14651858.CD004143.pub5.
17.
MikkolaTSSavolainen-PeltonenHTuomikoskiPet al.(2017) Lower death risk for vascular dementia than for Alzheimer's disease with postmenopausal hormone therapy users. Journal of Clinical Endocrinology and Metabolism102: 870–877. DOI: 10.1210/jc.2016-3590.
18.
MikkolaTSTuomikoskiPLyytinenHet al.(2015a) Estradiol-based postmenopausal hormone therapy and risk of cardiovascular and all-cause mortality. Menopause22(9): 976–983. DOI: 10.1097/GME.0000000000000450.
19.
MikkolaTSTuomikoskiPLyytinenHet al.(2015b) Increased cardiovascular mortality risk in women discontinuing postmenopausal hormone therapy. Journal of Clinical and Endocrinology Metabolism100: 4588–4594. DOI: 10.1210/jc.2015-1864.
20.
NICE (2015a) Menopause: Diagnosis and management. Available at: www.nice.org.uk/guidance/ng23 (accessed 7 May 2018).
OgerEAlhenc-GelasMLacutKet al.(2003) Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: A randomized trial. Arteriosclerosis, Thrombosis, and Vascular Biology23: 1671–1676. DOI: 10.1161/01.ATV.0000087141.05044.1F.
23.
PalmaFDella VecchiaECagnacciA (2016) Medical and patient attitude towards vaginal atrophy: The AGATA study. Climacteric13: 1–5. DOI: 10.1080/13697137.2016.1240770.
24.
PanayNKaluE (2009) Management of premature ovarian failure. Best practice & research. Clinical Obstetrics & Gynaecology23: 129–140. DOI: 10.1016/j.bpobgyn.2008.10.008.
25.
Podfigurna-StopaACzyzykAGrymowiczMet al.(2016) Premature ovarian insufficiency: The context of long-term effects. Journal of Endocrinology Investigation39(9): 983–990. DOI: 10.1007/s40618-016-0467-z.
26.
PortmanDGassM (2014) Genitourinary syndrome of menopause: New terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Menopause21(10): 1063–1068. DOI: 10.1016/j.maturitas.2014.07.013.
RossouwJEAndersonGLPrenticeRLet al.(2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. Journal of the American Medical Association288: 321–333.
30.
StanczykFZHapgoodJPWinerSet al.(2013) Progestogens used in postmenopausal hormone therapy: Differences in their pharmacological properties, intracellular actions, and clinical effects. Reviews in Endocrine and Metabolic Disorders34: 171–208. DOI: 10.1210/er.2012-1008.
31.
ZhuLJiangXSunYet al.(2016) Effect of hormone therapy on the risk of bone fractures: A systematic review and meta-analysis of randomized controlled trials. Menopause23(4): 461–470. DOI: 10.1097/GME.0000000000000519.
